Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
MELVILLE, N.Y. & SOUTH SAN FRANCISCO, Calif., Jul 13, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) and Genentech, Inc. today announced that SATURN, a pivotal Phase III study of...
MELVILLE, N.Y.--(BUSINESS WIRE)--July 6, 2005--OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
MELVILLE, N.Y., Jun 15, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the...
DEERFIELD, IL, June 4, 2009 – Astellas Pharma Global Development (“APGD”), a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that Dr. Betsy Garofalo has been hired...
Read more about Astellas Adds CNS Therapy Area Leader to Global R&D Team
DEERFIELD, IL, June 1, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Dan Dunham as the vice president of compliance. Dunham will be responsible for governance of the compliance...
Read more about Astellas Hires New Vice President of Compliance
Study is Second Positive Phase III Trial of Tarceva as First-Line Maintenance Therapy ORLANDO, Fla., May 30, 2009 (BUSINESS WIRE) -- OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that...
Deerfield, IL (May 28, 2009) – The Food and Drug Administration (FDA) has granted Astellas Pharma US, Inc. approval for the use of Prograf® (tacrolimus) in conjunction with mycophenolate...
DEERFIELD, IL, May 28, 2009 – Astellas Pharma US, Inc. (“Astellas”) recently hired Walt Johnston as vice president of marketing. Reporting directly to Patrick Shea, senior vice president of...
Read more about Astellas Announces New Vice President of Marketing
Data Showed Tarceva Improved PFS in Patients with Both Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma Patients with an EGFR Mutation Achieved a 10 Fold Increase in the Time Patients Live...
Arginine vasopressin (AVP) receptor antagonist now available in new premixed formulation DEERFIELD, Illinois, April 1, 2009 — Astellas Pharma US, Inc. today announced the commercial availability...
Follow U.S. news
